Macrogenics Inc
A biotech company that engineers antibody-based therapies to fight cancer. Its drug MARGENZA was approved in 2020 for HER2-positive breast cancer, and its DART platform builds proteins that bind two targets at once, steering immune cells toward tumors. Founded in 2000 in Rockville, Maryland, by a team of scientists, its name combines "macro," for the large protein molecules it builds, with "genics," echoing genetic engineering.
Granted 37.0K
Granted 31.3K
Granted 34.8K
Granted 3.8K
Granted 34.5K
Granted 3.8K
Granted 28.3K
Granted 28.3K
Granted 3.8K
Granted 3.8K
Granted 3.8K
Granted 3.8K
Granted 3.8K
Granted 3.8K
Granted 3.8K
Granted 5.3K
| Insider | Stake change | Holds now | Granted / vested | Bought | Sold |
|---|---|---|---|---|---|
| Koenig ScottDirector · 2 transactions | +4.5% | 867.2K | 37.0K | — | — |
| Karrels JamesSVP and CFO · 6 transactions | +7% | 206.0K | 31.3K | — | — |
| Bonvini EzioSr VP, Research & CSO · 6 transactions | +17.2% | 145.8K | 34.8K | — | — |
| Heiden William KDirector · 1 transaction | +3.4% | 114.8K | 3.8K | — | — |
| Risser Eric BlasiusPresident and CEO, Director · 6 transactions | +23.6% | 77.2K | 34.5K | — | — |
| Hurwitz EdwardDirector · 1 transaction | +8.5% | 47.8K | 3.8K | — | — |
| Spitznagel ThomasSr VP, Technical Ops · 6 transactions | +43.2% | 38.5K | 28.3K | — | — |
| Peters Jeffrey StuartSenior VP, GC, and Secretary · 6 transactions | +64.9% | 31.1K | 28.3K | — | — |
| Chhabra MeenuDirector · 1 transaction | +34.1% | 14.8K | 3.8K | — | — |
| Ferrante Karen JeanDirector · 1 transaction | +34.1% | 14.8K | 3.8K | — | — |
| Jackson Scott ThomasDirector · 1 transaction | +34.1% | 14.8K | 3.8K | — | — |
| Liu MargaretDirector · 1 transaction | +34.1% | 14.8K | 3.8K | — | — |
| O'Brien Federica F.Director · 1 transaction | +34.1% | 14.8K | 3.8K | — | — |
| Siegel Jay PhilipDirector · 1 transaction | +34.1% | 14.8K | 3.8K | — | — |
| Stump David CDirector · 1 transaction | +34.1% | 14.8K | 3.8K | — | — |
| Smith Beth AnnVP, Controller & Treasurer · 6 transactions | +32.6% | 13.2K | 5.3K | — | — |
Select a row to see that insider’s individual transactions. Sum of the holdings confirmed in the 12 months before this insider's last filing. A Form 4 reports a holding per line — held directly, or through a named trust, partnership or foundation, and in each share class separately — never a person’s total. Lines not restated in that time are left out and shown apart: an active filer restates what they still hold, so a line they did not restate is more often an entity since renamed, whose shares a successor line reports too. An amber marker means some were left out.